Christopher Paul Rusconi
Plus aucun poste en cours
Profil
Christopher Paul Rusconi was the founder of Regado Biosciences, Inc. which was founded in 2003, where he held the title of Chief Scientific Officer from 2009 to 2013.
He also worked as an Assistant Research Professor at Duke University Medical Center.
Rusconi received his undergraduate degree from the University of Kansas and his doctorate from the University of Colorado Boulder in 2003.
Anciens postes connus de Christopher Paul Rusconi
| Sociétés | Poste | Fin |
|---|---|---|
| Duke University Medical Center | Corporate Officer/Principal | - |
Regado Biosciences, Inc.
 Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Fondateur | - |
Formation de Christopher Paul Rusconi
| University of Kansas | Undergraduate Degree |
| University of Colorado Boulder | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Regado Biosciences, Inc.
Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Health Technology |
